InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Comparison of the effects of CYT107 vs Placebo administered IM at 10µg/kg twice a week for
two weeks on immune reconstitution of lymphopenic COVID-19 patients.